Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency

Дата публикации: 25-09-2026 17:40:05

Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments, and how to make them more effective.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Gut mRNA tech supercharges vaccine and GLP-1 delivery	0	8.96	01-10-2026
2	Automated lipid nanoparticle production could accelerate the development of RNA therapies	0	8.2	28-09-2026
3	Год на полке: мРНК-вакцина пережила комнатную температуру	0	16.25	29-09-2026
4	Wearable nanotech could combat nerve agents	0	7.93	29-09-2026
5	Modification of magnetic nanoparticles improves RNA isolation	0	6.4	25-09-2026
6	Scientists overcome key barrier to self-amplifying vaccines	0	9.51	28-09-2026
7	Dopamine-based nanotubes combine heat, electrical stimulation and antioxidant release for first time	0	9.03	28-09-2026
8	Система ИИ помогла сделать РНК-вакцины стабильными при комнатной температуре	0	13.61	28-09-2026
9	Tiny polymer particles keep water jets stable for longer	0	8.92	07-09-2026
10	Science & Medicine: Increasing vaccine rates to eliminate cervical cancer	0	6.6	06-09-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: phys.org.